Yale University Clinical Trials
Sponsors / Yale University
Yale University is listed as the lead sponsor on 473 clinical trials registered with ClinicalTrials.gov. Across the portfolio, 35 are in recruitment, 11 are active non-recruiting, and 329 have reached completion. 74 trials have been terminated or withdrawn. The most common reasons cited for termination include slow or insufficient recruitment, funding constraints. Across the portfolio, planned enrollment totals 111,999 participants. Data on this page mirrors the ClinicalTrials.gov registry as of the most recent refresh.
473
Total Trials
35
Recruiting
11
Other Active
329
Completed
74
Terminated / Withdrawn
111,999
Total Enrollment
Termination reasons: Other45% · Recruitment35% · Funding14% · Safety4% · Regulatory1% · PI/or_Site1%
Recent Terminations
- Acute Alcoholic Hepatitis"Slow accrual"
- Refractory Status Epilepticus"Unable to meet adequate enrolment numbers for feasibility."
- Domestic Violence"Site was unable to refer participants due to staffing issues post COVID"
- Opioid Use"Slow/low recruitment, unable to recruit"
- Elevated Blood Pressure"Unable to recruit."
- Alcohol Use Disorder"Ligand was not effective."
- COVID-19 Pneumonia"Study terminated due to lack of enrollment reflecting the decrease in number of COVID infections. There were no safety and/or efficacy concerns involved in the decision to stop enrollment."
- NCT04287790 Stopped Feb 2021Alcohol Use Disorder"COVID-19 disrupted recruitment"
- ADHD"Following Yale University resuming in-person research activities, the investigators no longer had dedicated funding for the study and were unable to secure additional funding to meet the research goals."
- Cocaine Use Disorder"Could not obtain additional funding to continue the research."
Active Trials (11 total)
- NCT05743673
- NCT02404688
- NCT02407808
- NCT02709954
- NCT02710097
- NCT02710331
- NCT04704271
- NCT02989948
- NCT04237701
- Ampullary Adenocarcinoma PHASE2NCT07282912
- NCT07433634
- NCT04355572
- NCT05989308
- NCT06474754
- NCT04242355
- NCT07200115
- NCT07038733
- NCT03592290
- NCT06689891
- Pancreatic Cancer PHASE2NCT03991962